News & Updates

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D
Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D
17 Dec 2023

Early albuminuria reduction with finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is responsible for a huge proportion of the treatment effect against CKD progression and facilitates a modest amount of the effect against cardiovascular outcomes, reports a study.

Albuminuria reduction accounts for treatment effect on CKD outcomes in T2D
17 Dec 2023